Ryboquin Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 1

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

Ryboquin General Information

Description

Developer of gene therapy designed to treat cancer patients. The company's gene therapy uses nano-technology, commercializes human cancer medicines, and tumor apoptosis enhancer drugs to optimize chemotherapy, enabling patients to receive effective oncology therapies at an affordable cost.

Contact Information

Website
www.ryboquin.co.uk
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Flat 2 Kirklee Gate
  • Glasgow G12 0SZ
  • Scotland, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Vertical(s)
Nanotechnology, TMT, Life Sciences, Oncology
Corporate Office
  • Flat 2 Kirklee Gate
  • Glasgow G12 0SZ
  • Scotland, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ryboquin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Nov-2021 Completed Startup
3. Early Stage VC 27-Jul-2017 Completed Startup
2. Early Stage VC 07-Jan-2016 $2.19M $2.19M Completed Startup
1. University Spin-Out 01-Mar-2013 Completed Startup
To view Ryboquin’s complete valuation and funding history, request access »

Ryboquin Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary 1
Ordinary
To view Ryboquin’s complete cap table history, request access »

Ryboquin Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ryboquin Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Truetide Venture Capital Minority
To view Ryboquin’s complete investors history, request access »

Ryboquin Acquisitions (1)

Ryboquin’s most recent deal was a Merger/Acquisition with Nanogenics for . The deal was made on 19-Jul-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nanogenics 19-Jul-2018 Merger/Acquisition Drug Delivery
To view Ryboquin’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Ryboquin FAQs

  • When was Ryboquin founded?

    Ryboquin was founded in 2013.

  • Where is Ryboquin headquartered?

    Ryboquin is headquartered in Glasgow, United Kingdom.

  • What is the size of Ryboquin?

    Ryboquin has 1 total employees.

  • What industry is Ryboquin in?

    Ryboquin’s primary industry is Drug Discovery.

  • Is Ryboquin a private or public company?

    Ryboquin is a Private company.

  • What is Ryboquin’s current revenue?

    The current revenue for Ryboquin is .

  • How much funding has Ryboquin raised over time?

    Ryboquin has raised $4.53M.

  • Who are Ryboquin’s investors?

    Truetide has invested in Ryboquin.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process